BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

403 related articles for article (PubMed ID: 30240508)

  • 1. Impact of anticoagulant choice on hospitalized bleeding risk when treating cancer-associated venous thromboembolism.
    Zakai NA; Walker RF; MacLehose RF; Adam TJ; Alonso A; Lutsey PL
    J Thromb Haemost; 2018 Dec; 16(12):2403-2412. PubMed ID: 30240508
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anticoagulation for the long-term treatment of venous thromboembolism in people with cancer.
    Kahale LA; Hakoum MB; Tsolakian IG; Matar CF; Terrenato I; Sperati F; Barba M; Yosuico VE; Schünemann H; Akl EA
    Cochrane Database Syst Rev; 2018 Jun; 6(6):CD006650. PubMed ID: 29920657
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative Effectiveness and Safety of Direct-acting Oral Anticoagulants and Warfarin in Patients with Venous Thromboembolism and Active Cancer: An Observational Analysis.
    Dawwas GK; Dietrich E; Smith SM; Davis K; Park H
    Clin Ther; 2020 Sep; 42(9):e161-e176. PubMed ID: 32768247
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recurrent venous thromboembolism in anticoagulated patients with cancer: management and short-term prognosis.
    Schulman S; Zondag M; Linkins L; Pasca S; Cheung YW; de Sancho M; Gallus A; Lecumberri R; Molnar S; Ageno W; Le Gal G; Falanga A; Hulegårdh E; Ranta S; Kamphuisen P; Debourdeau P; Rigamonti V; Ortel TL; Lee A
    J Thromb Haemost; 2015 Jun; 13(6):1010-8. PubMed ID: 25851122
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Trends in Anticoagulant Utilization and Clinical Outcomes for Cancer-Associated Thrombosis: A Multicenter Cohort Study in Thailand's Upper-Middle-Income Country Setting.
    Kengkla K; Nathisuwan S; Sripakdee W; Saelue P; Sengnoo K; Sookprasert A; Subongkot S
    JCO Glob Oncol; 2024 Feb; 10():e2300353. PubMed ID: 38422463
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association of Type of Oral Anticoagulant Dispensed With Adverse Clinical Outcomes in Patients Extending Anticoagulation Therapy Beyond 90 Days After Hospitalization for Venous Thromboembolism.
    Pawar A; Gagne JJ; Gopalakrishnan C; Iyer G; Tesfaye H; Brill G; Chin K; Bykov K
    JAMA; 2022 Mar; 327(11):1051-1060. PubMed ID: 35289881
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative Safety and Effectiveness of Direct Oral Anticoagulants and Warfarin during Chemotherapy in Cancer Patients with Venous Thromboembolism Aged 75 Years or Older: A Nationwide Inpatient Database Study.
    Iwai C; Jo T; Konishi T; Kumazawa R; Matsui H; Fushimi K; Yasunaga H
    Gerontology; 2023; 69(5):561-570. PubMed ID: 36502790
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risk Stratification for Bleeding Complications in Patients With Venous Thromboembolism: Application of the HAS-BLED Bleeding Score During the First 6 Months of Anticoagulant Treatment.
    Brown JD; Goodin AJ; Lip GYH; Adams VR
    J Am Heart Assoc; 2018 Mar; 7(6):. PubMed ID: 29514808
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinically relevant bleeding in cancer patients treated for venous thromboembolism from the CATCH study.
    Kamphuisen PW; Lee AYY; Meyer G; Bauersachs R; Janas MS; Jarner MF; Khorana AA;
    J Thromb Haemost; 2018 Jun; 16(6):1069-1077. PubMed ID: 29573330
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Direct Oral Anticoagulants for the Treatment of Acute Venous Thromboembolism Associated with Cancer: A Systematic Review and Meta-Analysis.
    Giustozzi M; Agnelli G; Del Toro-Cervera J; Klok FA; Rosovsky RP; Martin AC; Herold J; Tzoran I; Szmit S; Bertoletti L; Becattini C; Huisman MV
    Thromb Haemost; 2020 Jul; 120(7):1128-1136. PubMed ID: 32365386
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative Effectiveness of Anticoagulants in Patients With Cancer-Associated Thrombosis.
    Riaz IB; Fuentes H; Deng Y; Naqvi SAA; Yao X; Sangaralingham LR; Houghton DE; Padrnos LJ; Shamoun FE; Wysokinski WE; McBane RD
    JAMA Netw Open; 2023 Jul; 6(7):e2325283. PubMed ID: 37486628
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Direct oral anticoagulant (DOAC) versus low-molecular-weight heparin (LMWH) for the treatment of cancer-associated thrombosis (which agent for which patient).
    Pernod G; Joly M; Sonnet B
    J Med Vasc; 2020 Nov; 45(6S):6S17-6S23. PubMed ID: 33276939
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment Patterns and Clinical Outcomes in Korean Cancer Patients With Venous Thromboembolism: A Retrospective Cohort Study.
    Bang SM; Kang JH; Hong MH; Ahn JS; Oh SY; Baek JH; Choi YJ; Shin SH; Kim YJ; Gil HY; Park HE; Lee J; Park EL
    Clin Appl Thromb Hemost; 2021; 27():1076029620979575. PubMed ID: 33471574
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Periprocedural interruption of anticoagulation in patients with cancer-associated venous thromboembolism: An analysis of thrombotic and bleeding outcomes.
    Shaw JR; Douketis J; Le Gal G; Carrier M
    J Thromb Haemost; 2019 Jul; 17(7):1171-1178. PubMed ID: 31038838
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Thrombotic and bleeding outcomes following perioperative interruption of direct oral anticoagulants in patients with venous thromboembolic disease.
    Shaw J; de Wit C; Le Gal G; Carrier M
    J Thromb Haemost; 2017 May; 15(5):925-930. PubMed ID: 28296069
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical Outcomes of Direct Oral Anticoagulants vs Warfarin for Extended Treatment of Venous Thromboembolism.
    Fang MC; Reynolds K; Fan D; Prasad PA; Sung SH; Portugal C; Garcia E; Go AS
    JAMA Netw Open; 2023 Aug; 6(8):e2328033. PubMed ID: 37581888
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Transition of management strategies and long-term outcomes in cancer-associated venous thromboembolism from the warfarin era to the direct oral anticoagulant era.
    Chatani R; Yamashita Y; Morimoto T; Kaneda K; Mushiake K; Kadota K; Nishimoto Y; Ikeda N; Kobayashi Y; Ikeda S; Kim K; Inoko M; Takase T; Tsuji S; Oi M; Kimura T;
    Eur J Intern Med; 2024 May; 123():72-80. PubMed ID: 38278660
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative effectiveness and safety of direct oral anticoagulants (DOACs) versus conventional anticoagulation for the treatment of cancer-related venous thromboembolism: A retrospective analysis.
    Ross JA; Miller MM; Rojas Hernandez CM
    Thromb Res; 2017 Feb; 150():86-89. PubMed ID: 28064037
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Changing Treatment Patterns in Patients With Venous Thromboembolism in Taiwan.
    Lee CH; Fang CC; Tsai LM; Lin HW; Chen PS; Lin SH; Li YH
    Circ J; 2020 Jan; 84(2):283-293. PubMed ID: 31932560
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison Between Non-vitamin K Antagonist Oral Anticoagulants and Low-Molecular-Weight Heparin in Asian Individuals With Cancer-Associated Venous Thromboembolism.
    Chen DY; Tseng CN; Hsieh MJ; Lan WC; Chuang CK; Pang ST; Chen SW; Chen TH; Chang SH; Hsieh IC; Chu PH; Wen MS; Chen JS; Chang JW; See LC; Huang WK
    JAMA Netw Open; 2021 Feb; 4(2):e2036304. PubMed ID: 33533929
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.